Over a one-year follow-up period, the QoL remained stable, while the societal costs decreased in both G+/P- individuals and HCM patients, and a significant reduction in BoD was observed among symptomatic oHCM patients, in particular those classified as NYHA III.
R. Mangal, S. Schoonvelde, I. Wiethoff et al.· European Heart Journal· 0 citations
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiac disorder, yet remains substantially underdiagnosed in clinical practice. Although current guidelines define HCM primarily based on left ventricular wall thickness, this approach alone does not capture the full spectrum of disease expression. Compreh...
Viktoria Höller, P. Zwetsloot, V. Santner et al.· Heart Failure Reviews· 0 citations
Background: Genetic testing is a Class I recommendation for patients with hypertrophic cardiomyopathy (HCM). As knowledge and frameworks continue to evolve, genetic variant classifications may change with new evidence over time. Classifications rely on evidence sought from publicly available case data, improved classif...
S. Hespe, G. Powell, L. Catto et al.· medRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.